Frontrunner Kymera Claims Proof-Of-Concept For Protein Degrader Platform

Results From Sanofi-Partnered Asset

 
• By Andrew McConaghie

Kymera has unveiled the first placebo-controlled data from a protein degradation candidate, adding to heightened expectations for the novel modality.

MIT Hockfield Court, Stata Center in Kendall Square, Cambridge MA
Cambridge, MA -based Kymera has reached 'proof of concept' six years after its launch. • Source: Alamy

Kymera Therapeutics, one of the leaders in the hotly tipped targeted protein degradation (TPD) field, has unveiled early data which it claims are proof-of-concept for its lead candidate and its platform.

More from Immunological

More from Therapy Areas

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By Kevin Grogan

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 
• By Alaric DeArment

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By Joseph Haas

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.